

Afirma®

Genomic Sequencing Classifier

MORE ABOUT YOU.™

The thyroid nodule test that helps reveal more about you.
Ask your doctor if the Afirma test is right for you.

The Afirma test is an advanced diagnostic test that can help determine if thyroid surgery may be avoided or assist your physician to customize your treatment plan.¹

HERE'S HOW THE AFIRMA TEST WORKS:



STEP 1: FNA BIOPSY

Your physician will collect thyroid nodule cells with a very thin needle (FNA biopsy) for both cytopathology assessment and Afirma genomic evaluation. Collecting multiple samples at one time will allow you to avoid returning for a second procedure.

STEP 2: CYTOPATHOLOGY

Your thyroid nodule cells are then viewed by a cytopathologist—a doctor trained to examine cells under a microscope. If the result is benign, Afirma genomic testing is not necessary. In some instances, the cytopathology results are not clear, and this is called an indeterminate result. In other instances, the cytopathology results diagnose the nodule as malignant.

if not benign

STEP 3: AFIRMA GENOMIC TESTING

If your cytopathology is not benign, Afirma testing will then evaluate the genes in your thyroid nodule cells. When Afirma genomic testing identifies a sample as benign—which it does in approximately 2/3 of indeterminate nodules—the chance of cancer is very low.¹ If your cytopathology is malignant, Afirma testing may help inform the optimal approach to therapy. In the event of a Suspicious result, Afirma may identify variants or fusions that could help your physician guide their treatment decisions.

MORE ABOUT YOU.™

Your diagnostic questions need clear answers, right from the start. Get insights and answers to critical questions that can help you and your doctor confidently customize your care with the Afirma test.

Veracyte Customer Care is available to answer your questions at [1.888.9AFIRMA](tel:18889AFIRMA) (888.923.4762) or by e-mail at support@veracyte.com, Monday through Friday from 5:30am–5:00pm (Pacific).

Visit AskForAfirma.com to learn more about the Afirma test, a CLIA-validated Laboratory Developed Test (LDT).

Reference: 1. Ali SZ, et al. *Cancer Cytopathol.* 2019.



VERACYTE ACCESS—MAKING AFIRMA TESTING ACCESSIBLE TO ELIGIBLE PATIENTS IS OUR PRIORITY.

Veracyte is committed to providing patients with access to the Afirma test, regardless of their personal financial situation.



BROAD COVERAGE

Covered by Medicare and covered by most commercial payers (over 275 million patients)



COMMITMENT TO PATIENT ACCESS

The Veracyte Access Program can help reduce out-of-pocket costs for eligible uninsured and commercially insured patients. Please review table to the right to assess eligibility.

Received an EOB Letter?

You may receive an EOB (Explanation of Benefits) letter from your insurance company stating that Veracyte has submitted a claim to your insurance for reimbursement.

This is not a bill.

If you have any questions regarding your Veracyte bill, insurance Explanation of Benefits (EOB) or eligibility, [please contact a Veracyte Customer Care representative.](#)

We are here to help at **1.888.9AFIRMA** (888.923.4762)

Email: support@veracyte.com Fax: **650.243.6388**

VERACYTE ACCESS ELIGIBILITY FOR U.S. RESIDENTS

Household Size	Cost to Patient		
	\$0	\$100	\$295
1	\$45,180	\$52,710	\$60,240
2	\$61,320	\$71,540	\$81,760
3	\$77,460	\$90,370	\$103,280
4	\$93,600	\$109,200	\$124,800
5	\$109,740	\$128,030	\$146,320
2024 maximum household income*			

* Veracyte Access eligibility is based on total annual household income, insurance status, and household size. Some eligibility restrictions apply. Veracyte offers certain Afirma tests at a reduced cost to eligible applicants except where otherwise restricted. Residents of the United States, District of Columbia and Puerto Rico are eligible to apply. Veracyte Access does not constitute health insurance. You must meet certain income requirements set forth above. We may request documentation to verify your income, including recently filed tax returns and other supporting documentation. By requesting assistance, you certify, to the best of your knowledge, that you are eligible for assistance and that you have insufficient financial resources to pay for the ordered test. We may discontinue or change this program at any time for any reason without notice.

Detach here

Apply for Veracyte Access

Submit application within twelve months of Afirma test date to determine eligibility.

INSTRUCTIONS

1. Complete the Veracyte Access application on this page.
2. Sign and date the Veracyte Access application.
3. Send completed application to:
**Veracyte Access Program
6000 Shoreline Court, Suite 300
South San Francisco, CA 94080
or by fax at 650.243.6388**

ABOUT THE PATIENT

LAST NAME

FIRST NAME

STREET ADDRESS

APT.

CITY

STATE

ZIP

()

PHONE

DATE OF BIRTH (mm/dd/yyyy)

ABOUT THE PATIENT'S HOUSEHOLD

Number of people in the household, including dependents

1 2 3 4 Other Gross annual household income

I understand that I am providing written permission for Veracyte, Inc. to obtain information from financial reporting agencies or other sources to verify my eligibility for the Veracyte Patient Access Program. I authorize Veracyte to obtain such information solely to determine Patient Access Program eligibility.

If I do not have insurance, I certify that I am not eligible for Medicare, Medicaid or any other government health insurance and will not seek reimbursement from any insurance carrier or government agency for Afirma Thyroid FNA Analysis fees waived by Veracyte, Inc.

I certify that the information provided is true and accurate. I have read and understand the Veracyte Access Program requirements. I understand and agree that Veracyte, Inc. reserves the right at any time and without notice to modify or terminate this Program; and to audit the information provided on or enclosed with this application.

PATIENT SIGNATURE

DATE